Barcelona-based DeepUll, a medical diagnostics company, announced on Thursday, October 20, that it has raised €13M in a Series B round of funding led by Innvierte, part of the Spanish Ministry of Science and Innovation (CDTI), and an undisclosed strategic investor.
Existing investors Kurma Partners, Alta Life Sciences, UI Investissement (advised by Mérieux Equity Partners), and Axis Participaciones Empresariales also participated in the round.
The Spanish company says it will use the funds to advance the development of its sepsis recognition platform.
Sepsis is a potentially life-threatening condition caused by infection. It occurs when an infection triggers a chain reaction throughout the body. The reaction can cause inflammation, which can lead to organ failure and death if not treated immediately. Early sepsis recognition is vital in improving patient prognosis and reducing mortality.
DeepUll: What you need to know
Founded in 2020 by Jordi Carrera and Rafel Bru, who previously co-founded STAT-Dx, DeepUll develops culture-free diagnostic solutions for sepsis and acute infections.
The company’s product can detect more than 250 pathogens and about 15 resistance genes in one hour, with only 10mL of whole blood. Additionally, it provides phenotypic antimicrobial susceptibility results, reducing the unnecessary use of antimicrobials.
DeepUll’s product is powered by Artificial Intelligence (AI) and offers medical decision support across all phases of patient management, from early disease recognition to precise diagnostics, up to therapy guidance.
Jordi Carrera, Chief Executive Officer and co-founder of DeepUll, says, “Early identification of sepsis is absolutely crucial to a patient’s prognosis, but the tools caregivers have available today are woefully inadequate. Our mission is to change this, and this financing will allow us to ramp up our efforts to bring our first-in-class sepsis recognition platform to market. We are grateful to our existing investors and excited to welcome our new investors, which will strengthen our investor base.”